Major Considerations and Clinical Findings of COVID-19 and psoriasis: A Brief Systematic Review

Abstract

The effects on human health caused by COVID-19 lead to meta-inflammation processes. This process can aggravate psoriasis. This is a chronic inflammatory skin disease associated with significant morbidity. This problem affects around 2-3% of people worldwide. It was to demonstrate the main considerations about the relationship between COVID-19 and psoriasis, showing the possible mechanisms for the worsening of this dermatological disease. The systematic review rules of the PRISMA Platform were followed. The research was carried out from April to June 2022 in Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. It has been shown that patients with COVID-19 may have characteristics of hyperinflammation and metainflammation. The triggering or exacerbating factor of psoriasis can be medications, and in addition, patients with COVID-19 can have an exacerbation of psoriasis. The COVID-19 pandemic had a direct impact on dermatological diseases, especially psoriasis. The difficulty in accessing health services and the stress load caused exacerbations in psoriasis cases. Studies recommend avoiding classic immunosuppressive agents.